DWTX

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron® 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain ("CINP") phase 2b extension study. Based on a positive interim assessment

SCHEDULE 13G - Dogwood Therapeutics, Inc. (0001818844) (Subject)

10-Q - Dogwood Therapeutics, Inc. (0001818844) (Filer)

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the first qu

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (NASDAQ:DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b developme

DEF 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor T

PRE 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX", "Dogwood" or "the Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced FDA acceptance of an Investigational New Drug ("IND") application for its development candidate SP16, administered intravenously ("IV"), for the treatment of chemotherapy-induced pain and perip

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

10-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. "The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year," said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key Highlights In Decem

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

DEF 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

 - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain ("HALT-CINP") trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026. "If the HALT-CINP study is successful, Halenuron® would represent a new therapeutic agent for tre

EFFECT - Dogwood Therapeutics, Inc. (0001818844) (Filer)

PRE 14A - Dogwood Therapeutics, Inc. (0001818844) (Filer)

8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

S-3 - Dogwood Therapeutics, Inc. (0001818844) (Filer)